Alzheimer's disease (AD) - Epidemiology Forecast - 2034

Alzheimer's disease (AD) - Epidemiology Forecast - 2034

Key Highlights

DelveInsight’s analyst projects that the in 2023, the 7MM reported approximately 15,840 thousand diagnosed prevalent cases of Alzheimer’s disease, reflecting a significant disease burden. This high prevalence underscores the need for innovative treatments to address the rising impact on healthcare systems and patient care.

In 2023, among the EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of Alzheimer’s disease, representing 30% of the total cases, followed by France (24%). Analysis by DelveInsight’s experts indicates that the overall diagnosed prevalent cases of Alzheimer’s disease are expected to rise in the coming years.

According to DelveInsight analysis, nearly 2,325 thousand males and 4,650 thousand females were affected with Alzheimer’s disease in the US in 2023. DelveInsight estimates that these numbers will increase by 2034.

DelveInsight’s epidemiological model estimates that in 2023, the 75–84 age group in the EU4 and the UK had the highest Alzheimer’s disease cases, totaling 2,300 thousand. In contrast, the under 65 age group had the fewest cases, with nearly 125 thousand recorded.

DelveInsight’s estimates indicate that in 2023, Japan had approximately 2,470 thousand diagnosed prevalent cases of agitation associated with Alzheimer’s disease, a figure expected to grow by 2034. This behavioral symptom, marked by restlessness, irritability, aggression, and anxiety, significantly diminishes patient quality of life and heightens caregiver strain.

DelveInsight’s “Alzheimer’s Disease – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Alzheimer’s Disease, historical and forecasted epidemiology of Alzheimer’s Disease in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Alzheimer’s Disease Understanding

Alzheimer’s Disease Overview

Alzheimer’s disease is a progressive, irreversible neurological disorder, primarily impacting memory, reasoning, and cognitive abilities. It is the leading cause of dementia, responsible for roughly 60–80% of all cases. Though often emerging in the mid-60s, early-onset Alzheimer’s can affect individuals as young as their 40s or 50s, albeit rarely. Initial symptoms commonly include memory loss that significantly interferes with daily life, followed by confusion, language difficulties, impaired judgment, and behavioral changes. The disease’s exact cause remains unknown, but it is associated with abnormal accumulations of Amyloid Beta protein plaques and tau protein tangles in the brain, which disrupt cellular communication and lead to cell death. Increasing age and family history are recognized as key risk factors for Alzheimer’s disease.

Alzheimer’s Disease Diagnosis

Diagnosing Alzheimer’s disease remains challenging due to its gradual onset and overlapping symptoms with other cognitive disorders. The diagnosis primarily relies on clinical assessments, including a detailed medical history, cognitive tests, and evaluations of memory, reasoning, and language skills. Neuroimaging techniques, like MRI and PET scans, help detect structural brain changes, while biomarkers in cerebrospinal fluid can reveal amyloid and tau protein abnormalities. However, definitive diagnosis often occurs post-mortem through brain tissue examination.

The complexity of Alzheimer’s disease diagnosis is compounded by variability in symptom progression and the absence of a single diagnostic test. Additionally, the need for specialized tools and resources makes early diagnosis difficult, especially in low-resource settings. Misdiagnosis risks are high, which can delay appropriate interventions and add stress for patients and caregivers. Improved diagnostic accuracy through advancements in biomarker research and neuroimaging is critical to enabling timely, targeted treatments and addressing these diagnostic challenges in Alzheimer’s disease.

Further details related to diagnosis are provided in the report…

Alzheimer’s Disease Epidemiology

For the purpose of designing the patient-based model for Alzheimer’s Disease, the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Alzheimer’s Disease, Gender-specific Diagnosed Prevalent Cases of Alzheimer’s Disease, Age-specific Diagnosed Prevalent Cases of Alzheimer’s Disease, Severity-specific Diagnosed Prevalent Cases of Alzheimer’s Disease, Diagnosed Prevalent Cases of Agitation in Alzheimer’s Disease, and Diagnosed Prevalent Cases of Psychosis in Alzheimer’s Disease in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

DelveInsight’s analyst estimate that approximately 15,839 million Diagnosed Prevalent Cases of Alzheimer’s disease were found in 2023 in the 7MM.

In 2023, the United States accounted for about 44% of diagnosed Alzheimer’s disease cases across the 7MM, totaling 6,980 thousand cases. DelveInsight forecasts a rise in this figure by 2034, reflecting the growing burden of the disease. This trend underscores the increasing healthcare challenge posed by Alzheimer’s in the US during the forecast period.

In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Alzheimer’s disease in Japan were nearly 3,920 thousand in 2023.

In 2023, Japan recorded nearly 1,390 thousand diagnosed cases of Alzheimer’s disease in males and 2,530 thousand in females, reflecting a clear gender difference in disease prevalence. This disparity underscores the importance of considering gender-specific factors when addressing Alzheimer’s disease, including tailored treatment and care strategies for male and female patients.

Age-specific cases in the US are categorized into four groups: under 65, 65–74, 75–84, and 85+ years. In 2023, the 75–84 age group held the highest prevalence with nearly 2,790 thousand cases, whereas the under-65 group recorded the lowest with nearly 175 thousand cases.

Alzheimer’s disease is also classified by severity: mild cognitive impairment (MCI), mild, moderate, and severe dementia. Within EU4 and the UK, the MCI stage had the highest prevalence with around 2,560 thousand cases in 2023, while severe dementia showed the lowest with 645 thousand cases.

In 2023, the United States documented approximately 5,233 thousand diagnosed cases of agitation linked to Alzheimer’s disease, with projections indicating a continued rise by 2034. This growing prevalence highlights the escalating need for targeted interventions to manage agitation symptoms in Alzheimer’s patients, addressing both psychological and behavioral aspects of the disease.

In Japan, approximately 2,030 thousand cases of psychosis related to Alzheimer’s disease were reported in 2023, with the number expected to increase in the coming years. This upward trend emphasizes the growing burden of Alzheimer’s disease-associated psychosis and the need for effective treatments to manage these complex symptoms within the Japanese population.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Washington University School of Medicine, St. Louis, US; University of Nevada, US; Hannover Medical School, Germany; Universite Paris Saclay, France; Università di Palermo, Italy; Hospital Virgen De La Salud, Spain; University College London, the UK; Kyoto University, Japan and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Alzheimer’s Disease, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Alzheimer’s Disease Report Insights

Patient Population

Country-wise Epidemiology Distribution

Total Diagnosed Prevalent Cases of Alzheimer’s Disease

Gender-specific Diagnosed Prevalent Cases of Alzheimer’s Disease

Age-specific Diagnosed Prevalent Cases of Alzheimer’s Disease

Diagnosed Prevalent Cases of Alzheimer’s Disease Based on Severity of Airflow Limitation

Diagnosed Prevalent Cases of Alzheimer’s Disease Based on Symptoms and Exacerbation History

Alzheimer’s Disease Report Key Strengths

11 years Forecast

The 7MM Coverage

Alzheimer’s Disease Epidemiology Segmentation

Alzheimer’s Disease Report Assessment

Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of Alzheimer’s Disease? What will be the growth opportunities across the 7MM concerning the patient population of Alzheimer’s Disease?

What is the historical and forecasted Alzheimer’s Disease patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Why is the diagnosed prevalent cases of Alzheimer’s Disease in Japan lower than the US?

Which country has a high patient share for Alzheimer’s Disease?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the Alzheimer’s Disease prevalence cases in varying geographies over the coming years.

A detailed overview of Gender and Age Grade-specific diagnosed prevalence of Alzheimer’s Disease, along with diagnosed prevalence of Alzheimer’s Disease Based on severity of airflow limitation and diagnosed prevalence of Alzheimer’s Disease based on symptoms and exacerbation history.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Alzheimer’s Disease Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Alzheimer’s Disease cases in 2023?

The highest cases of Alzheimer’s Disease was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Alzheimer’s Disease cases in 2023?

The highest cases of Alzheimer’s Disease were found in the US among the 7MM in 2023.